Favipiravir

I. Assessment

A. Policy and Research Question

Policy Question:

Should the Philippine government introduce favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?

       Research Questions:

    1. What are the current country TGs or CPGs which recommend the use of favipiravir in treating patients with COVID-19?
    2. What is the clinical efficacy/ effectiveness and safety of favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versusthe DOH-PSMID recommended guidelines as of March 31?
    3. Does favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens represent value for money for the treatment of patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?

B. Protocol: Not available.

C. Reviewers: Health Technology Assessment Unit, DOH

D. Start of Review:  March 26, 2020

E. End of Review: April 8, 2020

II. Recommendation

Evidence summary: https://bit.ly/ESFavipiravir

Rapid review:  https://bit.ly/RRFavipiravir

III. Decision

Not Available

 

HTAC Recommendation Preview:

Favipiravir_KDD.JACP_.AJG-pages-5